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Abstract
Background: Type 2 diabetes is characterized by pancreatic b-cell dysfunction and is associated with low-grade
inflammation. Recent observations suggest that the signalling cascade activated by lipopolysaccharides (LPS) binding to
Toll-Like Receptor 4 (TLR4) exerts deleterious effects on pancreatic b-cell function; however, the molecular mechanisms of
these effects are incompletely understood. In this study, we tested the hypothesis that LPS alters insulin gene expression via
TLR4 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) in islets.
Methodology/Principal Findings: A 24-h exposure of isolated human, rat and mouse islets of Langerhans to LPS dose-
dependently reduced insulin gene expression. This was associated in mouse and rat islets with decreased mRNA expression
of pancreas-duodenum homebox-1 (PDX-1) and mammalian homologue of avian MafA/l-Maf (MafA). Accordingly, LPS
exposure also decreased glucose-induced insulin secretion. LPS repression of insulin, PDX-1 and MafA expression, as well as
its inhibition of insulin secretion, were not observed in islets from TLR4-deficient mice. LPS inhibition of b-cell gene
expression in rat islets was prevented by inhibition of the NF-kB pathway, but not the p38 mitogen-activated protein kinase
(p38 MAPK) pathway.
Conclusions/Significance: Our findings demonstrate that LPS inhibit b-cell gene expression in a TLR4-dependent manner
and via NF-kB signaling in pancreatic islets, suggesting a novel mechanism by which the gut microbiota might affect
pancreatic b-cell function.
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Introduction
The prevalence of diabetes mellitus is rising across the world,
closely associated with a dramatic increase in obesity rates. Type 2
diabetes (T2D) is characterized by defective insulin secretion from
the pancreatic b-cell and diminished insulin sensitivity in
peripheral tissues. According to the ‘‘metainflammation’’ hypoth-
esis, T2D is also considered as a state of chronic, systemic and low-
grade inflammation [1]. Circulating levels of several inflammatory
mediators such as acute-phase protein, cytokines and markers of
endothelial activation are elevated in T2D patients (reviewed in
[2]). Pancreatic b-cells are capable, under certain pathological
circumstances, of producing the proinflammatory cytokine
interleukin-1b (IL-1b) which can in turn impair b-cell function
and induce apoptosis [3,4]. The proof-of-concept that inflamma-
tion plays a role in the pathogenesis of T2D has been provided by
the results of a clinical trial showing that administration of an IL-1-
receptor antagonist (IL-1Ra) improves glycemic control in T2D
patients [5].
In recent years, the gut microbiota has been proposed as an
environmental factor increasing the risk of metabolic disorders
such as T2D, leading to the endotoxemia concept [6]. Accord-
ingly, subjects with T2D present an altered microbiota reported to
be enriched in gram-negative bacteria [7,8] which express
lipopolysaccharides (LPS). This is associated with increased
circulating levels of LPS and low-grade endotoxemia which plays
a role, at least in part, in the onset of metabolic diseases. In support
of this, modulation of the gut microflora in rodents reduces
circulating levels of LPS and protects from diet-induced glucose
intolerance, insulin resistance and inflammation [9–13]. Impor-
tantly, evidence for this concept is emerging in humans [14,15].
Circulating LPS bind Toll-Like Receptor 4 (TLR4) and its co-
receptors CD14 and MD-2. TLR4 homodimerizes and recruits
the adaptor proteins Myeloid differentiation primary response
gene 88 (MyD88) and Toll-IL-1 receptor (TIR) domain-containing
adapter-inducing interferon-b (TRIF) through their TIR domains,
and activates nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-kB), p38 mitogen-activated protein kinases (p38
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inflammatory gene expression. TLR4 is present in antigen-
presenting cells, but also in non-immune cells such as adipocytes
[16], myocytes [17] and pancreatic b-cells [18–20]. Interestingly,
recent evidence suggests that activation of TLR4 signalling can
induce both insulin resistance and pancreatic b-cell dysfunction.
Thus, deletion or mutation of the gene encoding TLR4 was shown
to protect against fatty acid-induced insulin resistance and diet-
induced obesity [16,17,21–23]. In addition, LPS inhibit insulin
secretion and insulin gene expression in isolated islets of
Langerhans and in b-cell lines [18–20]. However, the precise
molecular and signalling mechanisms by which LPS affect b-cell
function are unknown.
The aim of this study was to determine the molecular
mechanisms by which LPS impair insulin gene expression, and
to test the hypothesis that this effect involves TLR4 and NF-kB
signalling.
Results
LPS impair insulin pre-mRNA expression in isolated rat
and human islets
First we examined the effects of LPS on insulin gene expression
in isolated islets. To this aim we measured insulin pre-mRNA,
which has a much shorter half-life than mature insulin mRNA and
more directly reflects insulin transcription rates [24]. Isolated rat
(Fig. 1A) and human (Fig. 1B) islets were exposed for 24 h to
increasing concentrations of LPS. LPS dose-dependently de-
creased insulin 2 pre-mRNA expression in rat isolated islets
(Fig. 1A; n=3–6; p,0.05). Human islets were much more
sensitive to LPS than rat islets, with a significant decrease in
human insulin pre-mRNA expression observed at 0.1 ng/mL
(Fig. 1B; n=2–6; p,0.05). At the highest concentration of LPS
used in these experiments (5 mg/ml), we could not detect any cell
death by caspase-3/7 activity (data not shown). These results
indicate that LPS inhibit insulin gene expression in isolated islets.
Exposure to LPS represses insulin, pancreas-duodenum
homeobox-1 (PDX-1) and mammalian homolog of avian
MafA/L-Maf (MafA) gene expression via TLR4
To investigate the role of TLR4 in the inhibitory effects of LPS
on the insulin gene, islets from TLR4-deficient C3H/HeJ mice,
which harbour a missense mutation in the tlr4 gene rendering
TLR4 unable to signal in response to LPS, and wild-type (WT)
C3H/HeOuJ littermates were isolated and exposed for 24 h to 2.8
or 16.7 mM glucose in the presence or absence of 5 mg/mL LPS.
Palmitate (0.5 mM) and IL-1b (0.5 ng/mL) were used as positive
controls. As expected, exposure to glucose increased insulin 2 pre-
mRNA levels, and this was greatly reduced in the concomitant
presence of palmitate or IL-1b, both in WT and TLR4-deficient
islets. Consistent with the results shown in Fig. 1A, LPS reduced
insulin 2 pre-mRNA expression in WT islets (Fig. 2A; n=6;
p,0.05). However, no significant reduction in insulin 2 pre-
mRNA was observed in response to LPS in TLR4-deficient islets
(Fig. 2A).
Insulin gene expression in adult b-cells is regulated, amongst
others, by the glucose-responsive transcription factors PDX-1 and
MafA [25]. To examine whether LPS inhibition of insulin gene
expression involves these transcription factors, we measured their
mRNA levels in islets from WT and TLR4-deficient mice cultured
under similar conditions as above. As expected, both palmitate
and IL-1b suppressed PDX-1 and MafA mRNA expression in
both WT and TLR4-deficient mice (Fig. 2B & C). LPS inhibited
both PDX-1 and MafA mRNA levels in islets isolated from WT
mice, but not in islets isolated from TLR4-deficient mice. Taken
together, these data demonstrate that LPS repress insulin, PDX-1
and MafA gene expression in islets and that this effect requires
TLR4.
Exposure to LPS does not affect PDX-1 nuclear
localization
Chronic exposure to palmitate inhibits insulin gene expression
in islets in part via exclusion of PDX-1 from the nuclear
compartment [26–28]. To examine whether LPS act via a similar
mechanism, a PDX-1-GFP construct was overexpressed in HIT-
T15 insulin-secreting cells and exposed to 0.1 mM glucose or
5.0 mM glucose in the presence or absence of 0.5 mM palmitate
or increasing doses of LPS for 24 h. PDX-1 expression and
subcellular localization were visualized using GFP fluorescence
under a confocal microscope (Fig. 3A–F). Nuclei were visualized
using DAPI staining (Fig. 3G–L). As expected, PDX-1 expression
at 0.1 mM glucose was low in intensity and restricted to the cytosol
(Fig. 3A&G). In response to high (5.0 mM) glucose, PDX-1 was
predominantly localized in the nucleus (Fig. 3B&H). As we
previously observed [27,28], addition of palmitate restricted PDX-
1 localization to the cytosolic compartment (Fig. 3C&I). In
contrast, exposure of HIT-T15 cells to increasing doses of LPS did
Figure 1. Exposure to LPS dose-dependently represses insulin
pre-mRNA expression in isolated rat and human islets. Insulin
pre-mRNA levels in response to increasing doses of LPS in isolated rat
(A) and human (B) islets. Pre-mRNA levels were measured by RT-PCR
and normalized to b-actin mRNA levels. Data are mean 6 S.E.M. of 2–6
independent experiments; *p,0.05 vs 0 pg/mL.
doi:10.1371/journal.pone.0036200.g001
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suggests that LPS does not alter PDX-1 subcellular localization.
LPS inhibit insulin secretion in WT but not TLR4-deficient
mice
LPS have been reported to inhibit glucose-induced insulin
secretion (GSIS) in isolated islets [18,20]. To assess the role of
TLR4 in the impairment of GSIS by LPS, islets from WT and
TLR4-deficient mice were cultured for 24 h at 16.7 mM glucose
in the presence or absence of 5 mg/mL LPS, after which GSIS was
measured in 1-h static incubations (Fig. 4). Basal insulin secretion
was not significantly different between WT and TLR4-deficient
islets in the absence or presence of LPS. Stimulated insulin release
(in response to 16.7 mM glucose) from WT islets was slightly but
significantly lower in the presence of LPS (Fig. 4A; n=5; p,0.05).
Moreover, this effect appeared to require the presence of TLR4
since GSIS from islets isolated from TLR4-deficient mice was not
affected by LPS (Fig. 4A; n=5; ns). Insulin content from islets
isolated from both genotypes trended lower after LPS exposure
(Fig. 4B), such that when normalized to intracellular insulin
content, the difference in GSIS between LPS-exposed and control
WT islets was no longer significant (Fig. 4C). These results suggest
that LPS decrease GSIS and that this effect might be in part due to
reduction in intracellular insulin stores.
LPS inhibition of insulin, PDX-1, and MafA gene
expression is prevented by inhibition of NF-kB but not
p38 MAPK
TLR4 signalling involves both the NF-kB and p38 MAPK
pathways. To examine the implication of these pathways in LPS
inhibition of b-cell gene expression, we used the soluble p38
MAPK inhibitor SB202190 (10 mM) and the NF-kB inhibitor
IKK-2 Inhibitor IV (10 mM) (Fig. 4) in isolated rat islets cultured
for 24 h at 16.7 mM glucose in the presence or absence of 10 ng/
mL LPS. IL-1b (0.5 ng/mL) was used as a positive control known
to signal via NF-kB [3]. As observed in Fig. 2 in mouse islets, both
LPS and IL-1b decreased insulin 2 pre-mRNA expression in rat
islets (Fig. 5A). This was completely prevented in the presence of
the NF-kB inhibitor, but not of the p38 MAPK inhibitor (Fig. 5A;
n=3–4; p,0.05). In addition, the NF-kB inhibitor, but not the
p38 MAPK inhibitor, completely prevented the decrease in PDX-
1 (Fig. 5B; n=4; p,0.05) and MafA (Fig. 5C; n=4; p,0.05)
expression in response to LPS. Using nuclear extracts, we also
examined NF-kB nuclear expression by immunoblotting in rat and
human isolated islets exposed for 24 h to 16.7 mM glucose in the
presence or the absence of 50 or 100 ng/mL LPS. Consistent with
the results shown in Fig. 5, nuclear extracts from both rat and
human islets exposed to LPS were enriched in the p65 subunit of
NF-kB (Fig. S1A&B; n=3; p,0.05). In addition, expression of the
NF-kB target gene TNF-a was increased in rat islets after a 24-h
exposure to 10 ng/mL LPS (Supp.Fig. 1C; n=4; p,0.05),
confirming activation of the pathway. These data therefore
demonstrate that LPS inhibition of insulin, PDX-1, and MafA
gene expression in islets requires TLR4 and NF-kB signalling.
Discussion
TLRs are one of the most ancient and conserved components of
the innate immune system and play key roles in recognizing
pathogen-associated molecules such as LPS. As many as 12 and 10
different isoforms of TLRs have been identified in humans and
rodents, respectively. Pancreatic b-cells express significant levels of
TLR4 which render them sensitive to LPS [18–20]. This study
was designed to identify the molecular mechanisms underlying the
deleterious effects of LPS on pancreatic b-cell function. Our results
uniquely demonstrate the requirement for TLR4 and NF-kB
signalling in LPS impairment of b-cell gene expression.
Insulin gene expression, essentially restricted to pancreatic b-
cells in adults, is tightly regulated by a highly sophisticated
transcriptional network. In response to stimulatory glucose
conditions, PDX-1, MafA and BETA2/NeuroD bind respectively
to the A3, C1 and E1 cis-acting DNA elements on the proximal
region of the insulin promoter and activate transcription in a
Figure 2. Exposure to LPS decreases insulin, PDX-1 and MafA
gene expression in isolated islets via TLR4. (A) Insulin pre-mRNA
expression (B) PDX-1 mRNA expression and (C) MafA mRNA expression
in islets isolated from WT and TLR4-deficient mice exposed for 24 h to
2.8 (2.8 G) and 16.7 mM (16.7 G) glucose in the presence or absence of
0.5 mM palmitate (PA), 0.5 ng/mL IL-1b or 5 mg/mL LPS. mRNA levels
were measured by RT-PCR and normalized to b-actin mRNA levels. Data
are mean 6 S.E.M. of 6 independent experiments; *p,0.05.
doi:10.1371/journal.pone.0036200.g002
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addition, glucose stimulates MafA expression [30] and promotes
PDX-1 translocation from the cytoplasm to the nucleus [31]. On
the other hand, insulin gene expression is altered under
pathological circumstances, such as chronically excessive levels of
glucose or fatty acids [32]. Thus, elevated fatty acids inhibit insulin
gene expression via impaired PDX-1 nuclear localization and
decreased binding of PDX-1 and MafA to the insulin promoter
[27,28,33].
In the present study, we confirmed that LPS impair insulin gene
expression in human islets [18]. Importantly, we found human
islets to be much more sensitive to LPS than rat islets, as insulin
pre-mRNA levels were significantly decreased in human islets at
the lowest dose of LPS used in this study (0.1 ng/mL). Since
circulating LPS concentrations are reported to be in the ng/mL
range in endotoxemia associated with metabolic diseases [15], our
results suggest that LPS inhibition of insulin gene expression might
occur in vivo in humans.
Using isolated islets from a mouse line harboring a TLR4
mutation that renders it unresponsive to LPS, we further showed,
to our knowledge for the first time, that TLR4 is required for the
effects of LPS, but not those of palmitate, on insulin gene
expression. This is in contrast to a recent study reporting a role for
TLR4 in mediating palmitate-induced apoptosis in insulin-
secreting INS1 cells [34], a discrepancy which might be explained
by different mechanisms underlying fatty-acid cytotoxicity vs. their
effects on the insulin gene, and/or differences between cell lines
and primary islets. We have previously shown that exposure of
isolated islets to exogenous palmitate leads to an increase in
intracellular ceramide content via de novo synthesis [33]. Ceramide
generation has recently been shown to mediate saturated fatty
acid-induced insulin resistance in skeletal muscle via TLR4
signalling [35]. In contrast, our results showing that palmitate
inhibition of insulin gene expression still occurs in the absence of a
functional TLR4 indicate that TLR4 signalling is dispensable for
fatty-acid-induced b-cell dysfunction. Our results also show that
LPS reduce PDX-1 and MafA mRNA expression in a TLR4-
related manner without affecting PDX-1 nuclear localization. This
mechanism of action is therefore different from that of palmitate,
which affects PDX-1 and MafA expression as well as PDX-1
nuclear translocation ([27,28] and Fig. 3).
It has been previously shown that exposure of isolated islets or
b-cell lines to LPS decreases insulin secretion [18,20]. We
confirmed that GSIS was reduced in isolated mouse islets in
response to LPS and showed that this requires a functional TLR4.
Our results are consistent with previous studies [18,20], but not
with a recent report by Kiely et al. [19] in insulin-secreting BRIN-
BD11 cells. This discrepancy might be explained by differences
between clonal cells and primary islets. Alternatively, the net effect
of LPS on insulin secretion might depend on whether or not the
results are normalized to insulin content. Indeed, in our study
GSIS was no longer significantly altered by LPS when expressed as
a percentage of intracellular insulin content, suggesting that
inhibition of insulin biosynthesis might account, at least in part, for
the reduced secretion, although this remains to be directly tested.
Finally, it is unlikely that the observed impairment of insulin gene
expression and insulin secretion in response to LPS merely results
from b-cell death, since we did not observed any activation of
caspase-3/7 under our experimental conditions.
The transcription factor NF-kB plays a central role in the innate
immune response and inflammation [36]. NF-kB is normally
retained in the cytoplasm via its binding to the inhibitor protein
kB( I kB). In response to stimuli such as IL-1b and LPS, the
interaction between inhibitor kinase (IKK) complex and IkB leads
to its phosphorylation. IkB is subsequently ubiquitinated and
degraded, enabling the release and translocation of NF-kB to the
nucleus and subsequent activation of its target genes such as TNF-
a [37,38]. In this study, we demonstrate that LPS exposure
increases NF-kBp65 nuclear localization in both rat and human
islets. We further showed that pharmacological suppression of the
NF-kB pathway completely restores insulin, PDX-1 and MafA
gene expression upon LPS exposure. The question then arises as to
how does NF-kB repress insulin gene expression in response to
LPS? In pancreatic b-cells, NF-kB is a key regulator of b-cell
survival and function [39–42]. Cytokine-induced NF-kB activation
has been reported to decrease PDX-1 mRNA expression [43].
Here, we report that LPS-induced activation of NF-kB reduces
insulin, PDX-1 and MafA mRNA levels. Thus, the reduction in
insulin gene expression by NF-kB could be indirectly due to its
inhibition of the two key transcription factors PDX-1 and MafA
(Fig. 6). Since there are no known NF-kB binding sites on the
insulin, PDX-1 or MafA promoters, inhibition of these genes by
NF-kB might be mediated through interactions with other
proteins. For instance, we observed that LPS increases CCAAT-
enhancer-binding protein b (C/EBPb) mRNA expression in
isolated islets from WT mice, but not in TLR4-deficient mice
Figure 3. PDX-1 cellular localization is not altered in response to LPS. HIT-T15 cells were transfected with a construct encoding a PDX-1-GFP
fusion protein. PDX-1 localization (green) (A–F) was visualized by GFP fluorescence using a laser-scanning confocal microscope in cells cultured in 0.1
and 5 mM glucose with or without 0.5 mM palmitate or increasing doses of LPS. 49,6-diamidino-2-phenylindole (DAPI) (blue) was used for nuclear
staining (G–L). Images are representative of 3 replicate experiments.
doi:10.1371/journal.pone.0036200.g003
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NF-kB might interact with C/EBPb, a known repressor of the
insulin gene [44–46], and increase C/EBPb binding to the insulin
promoter, as seen in other cell types [47,48], thereby repressing
insulin gene transcription. Another factor known to interact with
NF-kBp50 is the cAMP response element (CRE)-binding protein
(CREB) [49]. Since CREB induces insulin gene transcription
(reviewed in [50]), it is conceivable that an interaction between
CREB and NF-kB might prevent the binding of CREB to the
insulin promoter.
Our results reveal a role for TLR4 in LPS-mediated b-cell
dysfunction. TLR4 signalling has recently been reported to impair
insulin secretion and insulin mRNA expression in human islets via
Figure 4. Insulin secretion is reduced in response to LPS in WT
but not TLR4-deficient mouse islets. Insulin secretion (A), insulin
content (B) and insulin secretion normalized by insulin content (C) as
assessed in 1-h static incubations of isolated WT and TLR4-deficient
islets at basal (2.8 mM) and stimulatory (16.7 mM) glucose following a
24-h exposure to 16.7 mM glucose in the presence or absence of 5 mg/
mL LPS. Data are mean 6 S.E.M. of 5 independent experiments;
*p,0.05.
doi:10.1371/journal.pone.0036200.g004
Figure 5. Inhibition of NF-kB, but not p38 MAPK, restores
insulin, PDX-1, and MafA gene expression in islets exposed to
LPS. (A) Insulin pre-mRNA, (B) PDX-1 mRNA and (C) MafA mRNA
expression in isolated rat islets exposed for 24 h to 16.7 mM (16.7 G)
glucose in the presence or absence of 10 ng/mL LPS or 0.5 ng/mL IL-1b
with or without SB202190 (10 mM) and IKK-2 Inh IV (10 mM). Data are
mean 6 S.E.M. of 3–4 independent experiments; *p,0.05.
doi:10.1371/journal.pone.0036200.g005
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LPS were not examined. On the other hand TRIF, a critical
molecule in the TLR signalling pathway, was recently shown to be
important for normal b-cell function [52]. Thus, TRIF-null mice
exhibit hyperglycemia, impaired glucose tolerance, and defective
GSIS [52]. This suggests that TRIF might be required for normal
b-cell function but might become deleterious when chronically
activated in response to LPS. A similar dual effect has been
reported for NF-kB [53].
Finally, pancreatic b-cells express significant levels of TLR2
[20] which can recognize bacterial lipopeptides [54], including
LPS [55,56]. Moreover, TLR2 expression is induced by LPS [57]
and it has been recently proposed that up-regulation of TLR2 by
low levels of bacterial products can contribute to the mechanisms
by which the immune system increases its response to an infection
[58]. It is therefore possible that TLR2 amplifies TLR4 signalling
in response to LPS and might have contributed some of the effects
observed in this study, although this remains to be directly
examined.
In conclusion, this study uniquely demonstrates that impairment
of insulin gene expression by LPS involves decreased PDX-1 and
MafA mRNA levels and requires TLR4 and NF-kB signalling.
Importantly, the effects of LPS on the insulin gene in human islets
were observed at concentrations similar to the circulating levels
achieved during endotoxemia, suggesting that direct repression of
the insulin gene might contribute to the metabolic disturbances
associated with alterations of the microbiota.
Materials and Methods
Reagents
RPMI-1640, fetal bovine serum (FBS) and 49,6-diamidino-2-
phenylindole (DAPI) were obtained from Invitrogen (Burlington,
ON, Canada). PBS was obtained from Multicell. Fatty acid–free
Figure 6. Potential mechanism by which LPS repress insulin gene expression in isolated islets. Exposure to LPS activates the NF-kB
pathway in isolated islets and inhibits the expression of insulin, PDX-1 and MafA. The decrease in insulin expression might indirectly results from LPS
inhibition of PDX-1 and MafA. NF-kB could also inhibit insulin gene expression by interacting with other proteins such as C/EBPb and/or CREB, as
observed in other cell types.
doi:10.1371/journal.pone.0036200.g006
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TX, USA). SB202190 and IKK-2 Inhibitor IV were from
Calbiochem (EMD Biosciences, San Diego, CA, USA). Palmitate
(sodium salt), LPS (from Escherichia coli O111:B4) and all other
reagents (analytical grade) were from Sigma unless otherwise
noted.
Islet isolation and culture
Human islets - The use of human islets was approved by the
Institutional Ethics Committee of the Centre Hospitalier de
l’Universite ´ de Montre ´al (protocol #: ND-05-035). Isolated islets
from non-diabetic human cadaveric donors were obtained from
the NIH/NIDDK-supported Integrated Islet Distribution Pro-
gram (http://www.iidp.coh.org), and from the Clinical Islet
Laboratory at the University of Alberta. A written consent for
research from donor family was obtained for all donors.
Rodent islets - All procedures were approved by the
Institutional Committee for the Protection of Animals at the
Centre Hospitalier de l’Universite ´ de Montre ´al (protocol #:
An09027VPr). 8 week-old WT (C3H/HeOuJ) and TLR4-
deficient (C3H/HeJ) mice (harboring a missense mutation in the
tlr4 gene rendering TLR4 unable to signal in response to LPS)
were obtained from the Jackson Laboratories (Bar Harbor, Maine,
USA). 250–275 g male Wistar rats were obtained from Charles
River (St.-Constant, QC, Canada). Animals were housed under
controlled temperature (21uC) and a 12-h light-dark cycle with free
access to water and standard laboratory chow. Mice and rats were
anesthetized by IP injection of a Ketamine Hydrochloride
(Bimeda-MTC Animal Health Inc., Cambridge, ON)/Xylazine
(Bayer Inc., Toronto, ON) mixture and islets were isolated by
collagenase digestion and dextran density gradient centrifugation
as described [59].
Culture - Isolated islets were cultured in RPMI 1640 containing
10% FBS and exposed for 24 h to 2.8 or 16.7 mM glucose in the
presence or the absence of palmitate, IL-1b or LPS. Preparation of
the culture media containing palmitate was described previously
[33]. The final molar ratio of palmitate:BSA was 5:1. HIT-T15
cells (passage 75–78; kindly provided by R.P. Robertson (Pacific
Northwest Diabetes Research Institute, Seattle, WA, USA)) were
maintained in RPMI-1640 media containing 10% FBS and
11.1 mM glucose.
RNA extraction and real-time RT-PCR
Total RNA was extracted from aliquots of 150 islets each using
the RNeasy Qiagen micro-kit (Qiagen Inc., Mississauga, ON),
reverse transcribed, and real-time RT-PCR was carried out using
the Quantitect SYBR Green PCR Kit (Qiagen Inc., Mississauga,
ON), as previously described [28]. To amplify preproinsulin pre-
mRNA (Ins pre-mRNA), a forward primer was designed against a
sequence in exon 2 and a reverse primer designed against a
sequence in intron 2, as described [24]. Primers used for real-time
RT-PCR are listed in Table S1. All primer sets were designed
using Primer3 [60]. Results are expressed as the ratio of target
mRNA to b-actin mRNA.
PDX-1-GFP plasmids, transient transfections and
immunohistochemistry
A vector encoding a PDX-1-GFP fusion protein was generated
from a PDX1-cMyc construct [31]. Briefly, after stop codon
removal from the initial PDX1-cMyc sequence, the amplified 906-
nucleotide fragment was restricted by HindIII and KpnI, and
ligated into the mammalian expression vector pcDNA3.1-GFP in
line with the open–reading frame. For transient transfections,
HIT-T15 cells (passages 75 to 78) were seeded in 24-well plates at
a density of 80 000 cells/well 2 days before transfection. Cells were
transfected with a total of 0.8 mg PDX-1-GFP DNA and 2 mL
Lipofectamine 2000. Cells were fixed 24 h following treatments
(see results) with 3.7% formaldehyde for 30 min and permeabi-
lized with 0.1% Triton X-100 for 10 min and cold methanol for
20 min. After blocking with 5% normal horse serum, cells were
incubated with 10 mg/mL DAPI. Cells were observed under a
Leica TCS SP5 confocal microscope (636 Oil) (Leica Micro-
systems [Canada], Richmond Hill, ON).
Nuclear extracts and Western blot analyses
Nuclear proteins (10 mg) from isolated rat or human islets were
prepared and subjected to 10% SDS PAGE as previously
described [27]. Immunoblots were performed with anti-NF-
kBp65 (Cell signalling, Boston, MA, USA) and anti-histone
deacetylase 1 (HDAC1) (Millipore, Billerica, MA, USA) antibod-
ies. Signals were detected using a horseradish peroxidase-labeled
anti-rabbit IgG (BioRad) and enhanced chemiluminescence (ECL,
PerkinElmer Las Canada Inc.,Woodbridge, ON) on Kodak films
(Kodak, Rochester, NY, USA).
Caspase-3/7 activity assay
Caspase-3/7 activity was measured using a kit (Promega,
Madison, WI, USA) according to the manufacturer’s instructions.
Briefly, 25 islets were cultured for 24 h with increasing doses of
LPS (1 ng/mL to 5 mg/mL), and then incubated for 30 min. with
the Caspase-Glo 3/7 reagent. Fluorescence was measured using a
FluoStar-Optima microplate reader as described [61]. Results
were normalized per islet.
Insulin secretion in isolated islets
Insulin secretion was assessed in 1-h static incubations. Batches
of 10 islets each were washed twice in Krebs-Ringer buffer
containing 0.1% BSA and 2.8 mM glucose for 20 min at 37uC,
then incubated for 1 h at 37uC in either 2.8 or 16.7 mM glucose.
Each condition was run in triplicate. Intracellular insulin content
was determined after acidified-ethanol extraction. Insulin was
measured by radioimmunoassay (LINCO Research, St. Charles,
MO, USA).
Statistical analysis
Data are expressed as mean 6 SEM and were analyzed by
unpaired t-test or ANOVA with Dunnett’s or Bonferroni post-hoc
adjustments for multiple comparisons, as appropriate. p,0.05 was
considered significant.
Supporting Information
Figure S1 LPS activate NF-kB signaling and TNF-a
mRNA expression in isolated rat islets. (A) Representative
immunoblot of nuclear extracts using antibodies against NF-
kBp65 and HDAC1 in rat islets exposed for 24 h to 16.7 mM
(16.7 G) glucose in the presence or absence of 100 ng/mL LPS, or
human islets exposed for 24 h to 16.7 mM (16.7 G) glucose in the
presence or absence of 50 ng/mL LPS. (B) Quantification of NF-
kBp65 nuclear expression in rat islets exposed for 24 h to
16.7 mM (16.7 G) glucose in the presence or the absence of
100 ng/mL LPS (n=3) (C) TNF-a mRNA expression in rat
isolated islets exposed for 24 h to 16.7 mM (16.7 G) glucose in the
presence or the absence of 10 ng/mL LPS or 0.5 ng/mL IL-1b.
Data are mean 6 S.E.M. of 4 independent experiments. *p,0.05.
(TIF)
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